CREATE Medicines, Inc. (formerly Myeloid Therapeutics), a clinical-stage biotech pioneering in vivo multi-immune programming, today announced that clinical results from its Phase 1 MYE Symphony trial ...
I think these three make for excellent buys during November, as they should provide investors with impressive returns over ...
Leigh Day Solicitors said documents from Sheffield Hallam University suggested it had banned Professor Laura Murphy from continuing her research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback